TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from OncoSil Medical Ltd ( (AU:OSL) ).
OncoSil Medical Ltd has announced the quotation of 2,322 ordinary fully paid securities on the Australian Securities Exchange (ASX), effective from September 10, 2025. This move is part of the company’s strategy to enhance its financial flexibility and support its ongoing operations, potentially impacting its market position and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd operates in the medical industry, focusing on the development and commercialization of innovative medical devices. The company’s primary product is a targeted radioactive implant designed for the treatment of pancreatic and liver cancer, aiming to improve patient outcomes in these challenging areas.
Average Trading Volume: 41,049
Technical Sentiment Signal: Sell
Current Market Cap: A$22.78M
Learn more about OSL stock on TipRanks’ Stock Analysis page.